THE EFFECT OF THE CHOLECYSTOKININ RECEPTOR ANTAGONIST MK-329 ON MEAL-STIMULATED PANCREATICOBILIARY OUTPUT IN HUMANS

被引:56
|
作者
CANTOR, P
MORTENSEN, PE
MYHRE, J
GJORUP, I
WORNING, H
STAHL, E
SURVILL, TT
机构
[1] RIGSHOSP,DEPT CLIN CHEM & SURG GASTROENTEROL C,DK-2100 COPENHAGEN,DENMARK
[2] GLOSTRUP UNIV HOSP,DEPT MED GASTROENTEROL,GLOSTRUP,DENMARK
关键词
D O I
10.1016/0016-5085(92)91738-P
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To determine the physiological role of circulating cholecystokinin (CCK), the effect of the CCK receptor antagonist MK-329 on upper digestive processes was investigated in six normal volunteers after a mixed meal. In a double-blind, two-period, randomized crossover design, the subjects received either 10 mg MK-329 or placebo orally 3 hours 15 minutes before the meal, which contained 51CrCl3 as food marker. A five-lumen tube with the tip in the distal duodenum allowed continuous marker infusion (57Co-B12) and duodenal aspiration as well as recordings of antral and duodenal motility patterns via three pressure sensors. Postprandially, MK-329 caused a significant reduction of 30%-60% (P < 0.05) in pancreatic trypsin output during the initial three 15-minute periods; thereafter, the output was virtually the same than after placebo. Thus, the integrated enzyme response was only reduced by 15% (NS) during the 3-hour period beginning 15 minutes after the meal. In contrast, gallbladder contraction, determined by total bile acid excretion, was inhibited by 77% (P < 0.05), indicating a crucial role of CCK in regulating gallbladder motility. Except for the initial 30 minutes postprandially, MK-329 also induced a significant reduction in duodenal pH with mean values ranging from 3.5 ± 0.2 to 4.1 ± 0.3 compared with 4.5 ± 0.3 to 5.0 ± 0.4 after placebo (P < 0.05), probably because of lowered secretion of pancreatic bicarbonate. Gastric emptying rate was significantly accelerated by MK-329 during the initial 75 minutes after the meal, but the time for 50% emptying did not differ from placebo [127.5 ± 7.7 vs. 140.0 ± 9.0 minutes (NS)]. No changes were observed in the motility pattern of the proximal duodenum after feeding. Whereas MK-329 only caused a slight increase of the basal plasma CCK concentrations, the postprandial levels were markedly enhanced. Peak concentrations were 10.0 ± 1.3 vs. 4.0 ± 0.5 pmol/L after placebo (P < 0.001), and the integrated response exceeded the control value by 175% (P < 0.01). The results suggest that circulating CCK is not an essential mediator of the postprandial pancreatic enzyme secretion in humans, whereas it plays a critical role in gallbladder emptying. © 1992.
引用
收藏
页码:1742 / 1751
页数:10
相关论文
共 49 条
  • [1] INHIBITION OF CHOLECYSTOKININ-STIMULATED PANCREATICOBILIARY OUTPUT IN MAN BY THE CHOLECYSTOKININ RECEPTOR ANTAGONIST MK-329
    CANTOR, P
    OLSEN, O
    GERTZ, BJ
    GJORUP, I
    WORNING, H
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1991, 26 (06) : 627 - 637
  • [2] CHOLECYSTOKININ RECEPTOR ANTAGONIST MK-329 BLOCKS INTESTINAL FAT-INDUCED INHIBITION OF MEAL-STIMULATED GASTRIC-ACID SECRETION
    LLOYD, KCK
    MAXWELL, V
    KOVACS, TOG
    MILLER, J
    WALSH, JH
    GASTROENTEROLOGY, 1992, 102 (01) : 131 - 138
  • [3] MK-329 - A NONPEPTIDE CHOLECYSTOKININ-A ANTAGONIST
    EVANS, BE
    DRUG DEVELOPMENT RESEARCH, 1993, 29 (04) : 255 - 261
  • [4] HUNGER IN HUMANS INDUCED BY MK-329, A SPECIFIC PERIPHERAL-TYPE CHOLECYSTOKININ RECEPTOR ANTAGONIST
    WOLKOWITZ, OM
    GERTZ, B
    WEINGARTNER, H
    BECCARIA, L
    THOMPSON, K
    LIDDLE, RA
    BIOLOGICAL PSYCHIATRY, 1990, 28 (02) : 169 - 173
  • [5] REVERSAL OF THE ANORECTIC EFFECT OF (+)-FENFLURAMINE IN THE RAT BY THE SELECTIVE CHOLECYSTOKININ RECEPTOR ANTAGONIST MK-329
    COOPER, SJ
    DOURISH, CT
    BARBER, DJ
    BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (01) : 65 - 70
  • [6] REGULATION OF PANCREATIC ENDOCRINE FUNCTION BY CHOLECYSTOKININ - STUDIES WITH MK-329, A NONPEPTIDE CHOLECYSTOKININ RECEPTOR ANTAGONIST
    LIDDLE, RA
    GERTZ, BJ
    KANAYAMA, S
    BECCARIA, L
    GETTYS, TW
    TAYLOR, IL
    RUSHAKOFF, RJ
    WILLIAMS, VC
    COKER, LD
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (05): : 1312 - 1318
  • [7] EFFECT OF A CHOLECYSTOKININ ANTAGONIST ON MEAL-STIMULATED INSULIN AND PANCREATIC-POLYPEPTIDE RELEASE IN HUMANS
    HILDEBRAND, P
    ENSINCK, JW
    KETTERER, S
    DELCO, F
    MOSSI, S
    BANGERTER, U
    BEGLINGER, C
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (05): : 1123 - 1129
  • [8] EFFECT OF A NOVEL CHOLECYSTOKININ RECEPTOR ANTAGONIST, MK-329, ON PANCREATIC ENDOCRINE FUNCTION - IMPLICATIONS FOR THE PHYSIOLOGIC ROLE OF CCK
    LIDDLE, RA
    GERTZ, BJ
    KANAYAMA, S
    BECCARIA, L
    GETTYS, TW
    TAYLOR, IL
    RUSHAKOFF, RJ
    WILLIAMS, VC
    COKER, LD
    CLINICAL RESEARCH, 1989, 37 (02): : A369 - A369
  • [9] EFFECTS OF A NOVEL CHOLECYSTOKININ (CCK) RECEPTOR ANTAGONIST, MK-329, ON GALLBLADDER CONTRACTION AND GASTRIC-EMPTYING IN HUMANS - IMPLICATIONS FOR THE PHYSIOLOGY OF CCK
    LIDDLE, RA
    GERTZ, BJ
    KANAYAMA, S
    BECCARIA, L
    COKER, LD
    TURNBULL, TA
    MORITA, ET
    JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04): : 1220 - 1225
  • [10] LOCALIZATION OF PERIPHERAL CHOLECYSTOKININ RECEPTORS INVIVO USING THE CHOLECYSTOKININ ANTAGONIST [H-3] (+/-)-MK-329
    SADZOT, B
    SHELDON, J
    DANNALS, RF
    RAVERT, HT
    WAGNER, HN
    FROST, JJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 185 (2-3) : 195 - 201